Spots and clots – leave them or treat them?
Why and how to treat

Dennis M Jensen MD

The clinical indication for urgent endoscopy with combined diagnosis and treatment is bleeding that is severe enough to seek medical attention. The author uses stigmata of ulcer hemorrhage as a guide to endoscopic therapy. Active arterial bleeding, non-bleeding visible vessels and adherent nonbleeding clots are always treated endoscopically. In randomized trials, patients have demonstrated better outcomes from endoscopic therapies than from medical therapies. Flat spots, grey or black sloughs, and clear ulcer bases are not treated endoscopically. The clinical condition and the endoscopic appearance of the ulcer (ie, stigmata of hemorrhage) of the patient with upper gastrointestinal bleeding are used to determine the subsequent level of care (discharge, ward or intensive care).

Key Words: Endoscopy; Stigmata; Ulcer hemorrhage

The clinical indication for urgent endoscopy with combined diagnosis and treatment is bleeding that is severe enough to present for medical attention. The CURE Hemostasis Group uses stigmata of ulcer hemorrhage as a guide to endoscopic therapy. Active arterial bleeding, non-bleeding visible vessels and adherent nonbleeding clots are always treated endoscopically. In randomized trials, patients have demonstrated better outcomes from endoscopic therapies than from medical therapies. Flat spots, grey or black sloughs, and clear ulcer bases are not treated endoscopically. The clinical condition and the endoscopic appearance of the ulcer (ie, stigmata of hemorrhage) of the patient with upper gastrointestinal bleeding are used to determine the subsequent level of care (discharge, ward or intensive care).

The rational for endoscopic treatment is that, in randomized trials, patients treated by the CURE Hemostasis Group have demonstrated significantly better outcomes from endoscopic therapies (heater probe, bipolar, or combination injection and thermal) than from medical therapies (1-3). Persistent oozing without other stigmata is also treated, although this is not a very prevalent lesion, and in the absence of coagulopathies an advantage over medical therapy is difficult to document. The following are not treated endoscopically: flat spots, sloughs (grey or black) and clear ulcer bases. For such minor stigmata of ulcer hemorrhage, randomized trials have not shown a significant improvement over medical therapy (3), and in some older laser trials complications of therapy (such as induction of bleeding) were frequent (1,2) (Tables 1,2).

Most patients with ulcer hemorrhage start bleeding out of the hospital, and minor stigmata of ulcer hemorrhage are more prevalent. Figure 2 shows the prevalence of stigmata in large CURE studies.

In contrast, patients who develop hemorrhage after hospitalization for an unrelated problem (such as surgery or a comorbid illness) more often have major stigmata of ulcer hemorrhage and require endoscopic therapy (1,2).
STANDARD TECHNIQUES FOR THERMAL HEMOSTATIC THERAPY

The technique for endoscopic hemostatic therapy depends on the stigmata of ulcer hemorrhage and the experience of the endoscopists. The CURE Hemostasis Group’s standardized techniques have changed because combination therapy (adrenalin injection and thermal therapy) appears to be significantly better than monotherapy (thermal therapy alone with bipolar probe or heater probe) for active arterial bleeding (Hong Kong and CURE trials [4,5]) and for nonbleeding adherent clots (Mayo [6] and CURE [7] trials). With current sample sizes, a significant difference between thermal therapy (gold probe) and combination therapy (injection plus gold probe) for nonbleeding visible vessels has not been shown in one trial (CURE). The goal of controlling active arterial bleeding is more often achieved by four quadrant injections of adrenalin (1:10,000 concentration) in 0.5 to 1.0 mL aliquots, then coagulation with large diameter (10 French) gold probe directly on the bleeding point, tamponading it with firm pressure until the bleeding stops, then coagulating with long pulses (7 to 10 s in duration) at low power settings (15 to 20 W). Washing, suctioning and repositioning to tamponade the bleeding point facilitate complete control of the bleeding and flattening of the visible vessel, if present (1). As many pulses as necessary to control active bleeding are used. Four quadrant adrenalin injections can be repeated if bleeding is not well controlled with thermal coagulation. Heater probe (10 French) with five to six pulses of 30 J each per tamponade station (delivering 150 to 180 J) before moving the probe tip is also very effective for hemostasis of actively bleeding ulcers (1,2).

Among endoscopists and investigators, it is important to standardize the diagnosis for an adherent clot. The CURE hemostasis group uses the criteria listed in Table 3. Distinguishing an adherent clot from a nonbleeding visible vessel is also critical (Table 4).

For the nonbleeding visible vessel, coagulation with either gold probe or heater probe directly on the visible vessel, with the same techniques as those used to treat the active arterial bleeder, flattens the visible vessel, usually coagulates the underlying vessel well and significantly reduces rebleeding rates compared with medical therapy alone (1). Table 5 summarizes the management of nonbleeding visible vessels.

For the adherent, nonbleeding clot on an ulcer that obscures the underlying stigmata, the standard CURE hemostasis team approach is as follows: four quadrant adrenalin
injection followed by cold guillotining off the clot to reveal the underlying stigmata, if the clot cannot be washed or sectioned off first, and, finally, coagulation of the underlying visible vessel with thermal therapy (7). In a CURE multicentre trial, this combination therapy improved the outcomes of patients compared with medical therapy, whereas a previous trial demonstrated similar outcomes of three monotherapies – medical therapy alone, heater probe and injection (adenalin, then alcohol). Table 6 summarizes the management of adherent clots.

### Glossary
- **Nonbleeding visible vessel**
- **Adherent clot**

#### Table 4
Management of a nonbleeding visible vessel versus an adherent clot on ulcer

<table>
<thead>
<tr>
<th>Size</th>
<th>Colour</th>
<th>Form</th>
<th>Relation to stigmata</th>
<th>Rebleeding rate with medical therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small (mm)</td>
<td>Variable</td>
<td>Discrete</td>
<td>Is stigma</td>
<td>50%</td>
</tr>
<tr>
<td>Large (cm)</td>
<td>Red</td>
<td>Amorphous</td>
<td>Obscures stigma</td>
<td>30%</td>
</tr>
</tbody>
</table>

Data from references 1,2,7

### Table 5
Management of nonbleeding visible vessel after severe ulcer bleeding

1. The prevalence of a nonbleeding visible vessel after severe upper gastrointestinal hemorrhage is approximately 25%
2. The rebleeding rate is 40% to 50% on medical therapy
3. Endoscopic therapy reduces the rebleeding rate to 15% to 20%
4. A biopsy for Helicobacter pylori is performed, a proton pump inhibitor is given and a regular diet is maintained
5. The patient is retreated endoscopically for severe rebleeding
6. The patient is observed for 48 h and discharged

### Table 6
Management of an adherent clot on ulcer in a high risk patient after a severe upper gastrointestinal hemorrhage

1. The prevalence of an adherent clot is approximately 10% for severe upper gastrointestinal hemorrhage
2. The rebleeding rate is 30% to 40% with medical therapy
3. Monotherapies do not reduce the rebleeding rate
4. Adrenalin injection, washing, cold guillotining off the clot, and bipolar or heater probe coagulation reduce the rebleeding rate by <5%
5. The patient is biopsied for Helicobacter pylori and fed

### Using the Clinical Condition of the Patient and the Endoscopic Appearance of the Ulcer to Determine Subsequent Level of Care

In the tertiary care hospitals of the CURE Hemostasis Group, the clinical condition of the patient with upper gastrointestinal bleeding is used to determine whether patients should have continued hospitalization (in the intensive care unit, monitored bed or ward) or be followed up as an outpatient after endoscopy. The initial level of care is determined by clinical signs and assessment, such as the estimated severity of blood loss and consequent need for early resuscitation, determination of whether there is ongoing gastrointestinal bleeding or active gastrointestinal bleeding severe enough to warrant intensive care, and assessment of risk of the patient because of severe or unstable medical conditions (1-3). Because the CURE Hemostasis Group’s patient population is predominantly elderly people (older than 65 years of age), with a high prevalence of active or severe comorbid conditions, urgent endoscopy and stigmata of hemorrhage are not used to determine the initial level of care. However, endoscopic findings after admission are used to plan subsequent care after initial resuscitation and stabilization of comorbid medical conditions.

Patients who may be candidates for early endoscopy and triage to early discharge or ward hospitalization (8,9) are those who have less severe upper gastrointestinal hemorrhage, have stopped bleeding, have no significant comorbid conditions, are reliable and do not have significant hypovolemia. Patients with clean ulcer bases, flat spots or grey slough on endoscopy have very low rebleeding rates with medical therapy and, if they are reliable and able to return for outpatient follow-up, are reasonable candidates for outpatient management of their ulcer hemorrhage (8,9).

### References